Exploring new potential treatment options for your EoE?

Consider joining the ALAMERE study, a clinical trial for adults with eosinophilic esophagitis (EoE) investigating a new potential treatment for EoE symptoms and difficulty swallowing (dysphagia).

Exploring new treatment options for your EoE?

Consider joining the ALAMERE study, a clinical trial for adults with eosinophilic esophagitis (EoE) investigating a new potential treatment for EoE symptoms and difficulty swallowing (dysphagia).

Who can join the ALAMERE study?

You may be able to join the study if you meet the following requirements:

18 to 75 years old

Confirmed diagnosis of EoE

Must not have history or presence of other GI tract diseases (i.e. Celiac disease, Crohn’s disease)

18 to 75 years old

Confirmed diagnosis of EoE

Must not have history or presence of other GI tract diseases (i.e. Celiac disease, Crohn’s disease)

Other eligibility requirements will apply.

What will happen during the study?

Participation in the ALAMERE study lasts about 72 weeks. Study participants can expect the following:

Review & Sign the Informed Consent Form
The Informed Consent Form (ICF) contains information about the study including its goals, duration, benefits, risks, tests and procedures.
Run-In Period (4 weeks)
Consists of screening and baseline assessments
Treatment Period (Part A)
(24 weeks)
Participants will receive either the study drug or placebo every 4 weeks during the treatment period.
Open-Label Extension Period (Part B)
(28 weeks)
Eligible participants may continue receiving treatment in the open-label extension period. Participants will receive up to 7 doses of the study drug.
Safety Follow-up Period
(16 weeks)
Undergo study health assessments to allow the study doctor and staff to monitor your health and continue to observe your body’s reaction to the study drug.

Participation in a clinical study is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.

Interested in the ALAMERE study?

Take the pre-screener to see if you may qualify!

Take the Pre-Screener

About the Study Drug

What is the study drug?

The investigational study drug, solrikitug, aims to improve symptoms and reduce difficulty swallowing caused by eosinophilic esophagitis (EoE). While there are other treatments available for EoE, solrikitug has potential to treat EoE closer to the source rather than just treating the symptoms. The study drug is administered as an injection under the skin.

Will I receive the study drug?

Study participants in part A will receive either the study drug or placebo every 4 weeks. Participants are randomized into 4 groups in a 2:2:1:2 ratio, with the final group receiving placebo. This means that most participants will receive the study drug, and some participants will receive a placebo. Every participant who is eligible and continues to the Open-Label Extension period will receive the study drug.

What is a placebo?

A placebo looks like the study drug, but it does not contain any active drug. Some participants in the ALAMERE study will receive a placebo instead of the study drug. This lets researchers compare results across groups (placebo group compared to study drug group) to find out whether any results are from the study drug or from something else. Neither the participants nor the study team will know which group each participant was assigned to until after the study has ended.

What is an “investigational drug” (or study drug)?

Investigational means the drug is not approved by regulatory authorities like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and it can only be used in clinical research studies like ALAMERE.

About EoE

What is EoE?

Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus. The esophagus is the muscular tube that carries food and liquids from the mouth to the stomach. Individuals with EoE have white blood cells, called eosinophils, that build up in the lining of the esophagus which causes damage and inflammation. The longer this inflammation goes untreated, the more damage it can do to the esophagus over time.

EoE causes chronic dysphagia and food impaction. Dysphagia is a medical term for difficulty swallowing, and food impaction occurs when food becomes stuck in your esophagus.

What are Symptoms of EoE?

The symptoms of EoE vary by patient age but commonly include the following:

  • Difficulty swallowing, especially with solid foods
  • Food getting stuck in the esophagus
  • Chest/abdominal pain
  • Vomiting
  • Reflux that does not get better with medicines

Where can I learn more?

www.uniquity.com

Overview of Clinical Trials

Here are some common questions and answers about study participation.

Study Clinic Locations

Find a study clinic near you!

Use the filters, map, and listing to find the study clinic closest to you.

THIS WEBSITE IS INTENDED FOR U.S. AUDIENCES ONLY.

Stock photos posed by models
Copyright © 2024 ALAMERE Study